CAI - Caris Life Sciences, Inc. Stock Analysis | Stock Taper
Logo

About Caris Life Sciences, Inc.

https://www.carislifesciences.com

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms.

David Dean Halbert

CEO

David Dean Halbert

Compensation Summary
(Year )

Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public June 18, 2025
Method of going public Reverse Merger
Full time employees 1,769

ETFs Holding This Stock

Ratings Snapshot

Rating : D+

Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1

Most Recent Analyst Grades

Grade Summary

Buy 2
Outperform 1
Hold 1

Showing Top 4 of 4

Price Target

Target High $45
Target Low $30
Target Median $35
Target Consensus $36.25

Institutional Ownership